Stock listing
Frankfurt:ZVAA Cellectis S.A. Aktie
German listing (Frankfurt) of Cellectis S.A. · home listing Euronext:ALCLS
Follow Cellectis S.A. into a list and get an email when it puts out news.
Share price · FWB:ZVAA
€0.855 EUR -0.040 (-4.5%)
Close on Nov 20, 2026
- Day range
- €0.855 – €0.855 EURNov 20, 2026
- Market cap
- €86.13M EURAt the close on Nov 20, 2026 · price × 100.7M shares outstanding
- 52-week range
- €0.813 – €4.594 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €392 EURMedian day 0 shares · 59 days with no trades · last 3 months, Aug 20, 2026 – Nov 13, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ALCLS · Home | €0.91 EUR | -0.079 (-8.0%) | 285,262 | €0.999 | €0.999 | €0.903 | €0.989 | Close on Nov 20, 2026 |
| NASDAQ:CLLS | $0.921 USD | -0.063 (-6.4%) | 52,626 | $0.990 | $0.996 | $0.903 | $0.984 | Close on Nov 20, 2026 |
| OTC:CMVLF | $1.014 USD | +0.022 (+2.2%) | 4,000 | $1.014 | $1.014 | $1.014 | $0.992 | Close on Nov 20, 2026 |
| Frankfurt:ZVAA | €0.855 EUR | -0.040 (-4.5%) | — | €0.855 | €0.855 | €0.855 | €0.895 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 13, 2026 · FWB:ZVAA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.169 | -0.028 | -2.3% | €1.169 | €1.169 | €1.169 | 0 | |
| €1.197 | +0.267 | +28.7% | €1.197 | €1.197 | €1.197 | 0 | |
| €0.930 | -0.028 | -2.9% | €0.930 | €0.930 | €0.930 | 3,224 | |
| €0.958 | +0.066 | +7.4% | €0.958 | €0.958 | €0.958 | 0 | |
| €0.892 | +0.039 | +4.6% | €0.892 | €0.892 | €0.892 | 0 | |
| €0.853 | -0.104 | -10.9% | €0.853 | €0.853 | €0.853 | 0 | |
| €0.957 | +0.029 | +3.1% | €0.957 | €0.957 | €0.957 | 0 | |
| €0.928 | +0.085 | +10.1% | €0.928 | €0.928 | €0.928 | 0 | |
| €0.843 | -0.076 | -8.3% | €0.843 | €0.843 | €0.843 | 0 | |
| €0.919 | -0.050 | -5.2% | €0.919 | €0.919 | €0.919 | 0 | |
| €0.969 | -0.050 | -4.9% | €0.969 | €0.969 | €0.969 | 0 | |
| €1.019 | +0.147 | +16.9% | €1.019 | €1.019 | €1.019 | 0 | |
| €0.872 | +0.059 | +7.3% | €0.872 | €0.872 | €0.872 | 0 | |
| €0.813 | -0.024 | -2.9% | €0.813 | €0.813 | €0.813 | 0 | |
| €0.837 | +0.006 | +0.7% | €0.837 | €0.837 | €0.837 | 0 | |
| €0.831 | +0.013 | +1.6% | €0.831 | €0.831 | €0.831 | 0 | |
| €0.818 | -0.015 | -1.8% | €0.818 | €0.818 | €0.818 | 0 | |
| €0.833 | +0.012 | +1.5% | €0.833 | €0.833 | €0.833 | 0 | |
| €0.821 | -0.066 | -7.4% | €0.821 | €0.821 | €0.821 | 0 | |
| €0.887 | -0.047 | -5.0% | €0.887 | €0.887 | €0.887 | 0 | |
| €0.934 | -0.039 | -4.0% | €0.934 | €0.934 | €0.934 | 0 | |
| €0.973 | +0.023 | +2.4% | €0.973 | €0.973 | €0.973 | 0 | |
| €0.950 | -0.078 | -7.6% | €0.950 | €0.950 | €0.950 | 0 | |
| €1.028 | -0.044 | -4.1% | €1.028 | €1.028 | €1.028 | 0 | |
| €1.072 | +0.013 | +1.2% | €1.072 | €1.072 | €1.072 | 0 | |
| €1.059 | -0.104 | -8.9% | €1.059 | €1.059 | €1.059 | 20,000 | |
| €1.163 | -0.018 | -1.5% | €1.163 | €1.163 | €1.163 | 90 | |
| €1.181 | -0.053 | -4.3% | €1.181 | €1.181 | €1.181 | 0 | |
| €1.234 | +0.041 | +3.4% | €1.234 | €1.234 | €1.234 | 0 | |
| €1.193 | -0.016 | -1.3% | €1.193 | €1.193 | €1.193 | 0 | |
| €1.209 | -0.090 | -6.9% | €1.209 | €1.209 | €1.209 | 0 | |
| €1.299 | +0.031 | +2.4% | €1.299 | €1.299 | €1.299 | 0 | |
| €1.268 | +0.035 | +2.8% | €1.268 | €1.268 | €1.268 | 0 | |
| €1.233 | -0.003 | -0.2% | €1.233 | €1.233 | €1.233 | 0 | |
| €1.236 | +0.063 | +5.4% | €1.236 | €1.236 | €1.236 | 0 | |
| €1.173 | -0.017 | -1.4% | €1.173 | €1.173 | €1.173 | 0 | |
| €1.190 | -0.152 | -11.3% | €1.190 | €1.190 | €1.190 | 0 | |
| €1.342 | +0.066 | +5.2% | €1.342 | €1.342 | €1.342 | 0 | |
| €1.276 | +0.056 | +4.6% | €1.276 | €1.276 | €1.276 | 0 | |
| €1.220 | +0.040 | +3.4% | €1.220 | €1.220 | €1.220 | 0 | |
| €1.180 | +0.074 | +6.7% | €1.180 | €1.180 | €1.180 | 0 | |
| €1.106 | -0.206 | -15.7% | €1.106 | €1.106 | €1.106 | 0 | |
| €1.312 | -0.205 | -13.5% | €1.312 | €1.312 | €1.312 | 0 | |
| €1.517 | -1.078 | -41.5% | €1.517 | €1.517 | €1.517 | 0 | |
| €2.595 | -0.016 | -0.6% | €2.595 | €2.595 | €2.595 | 0 | |
| €2.611 | -0.055 | -2.1% | €2.611 | €2.611 | €2.611 | 0 | |
| €2.666 | -0.080 | -2.9% | €2.666 | €2.666 | €2.666 | 0 | |
| €2.746 | -0.076 | -2.7% | €2.746 | €2.746 | €2.746 | 0 | |
| €2.822 | +0.048 | +1.7% | €2.822 | €2.822 | €2.822 | 0 | |
| €2.774 | -0.105 | -3.6% | €2.774 | €2.774 | €2.774 | 0 | |
| €2.879 | +0.057 | +2.0% | €2.879 | €2.879 | €2.879 | 0 | |
| €2.822 | +0.106 | +3.9% | €2.822 | €2.822 | €2.822 | 0 | |
| €2.716 | -0.100 | -3.6% | €2.716 | €2.716 | €2.716 | 0 | |
| €2.816 | -0.153 | -5.2% | €2.816 | €2.816 | €2.816 | 0 | |
| €2.969 | -0.077 | -2.5% | €2.969 | €2.969 | €2.969 | 0 | |
| €3.046 | +0.140 | +4.8% | €3.046 | €3.046 | €3.046 | 0 | |
| €2.906 | +0.032 | +1.1% | €2.906 | €2.906 | €2.906 | 0 | |
| €2.874 | +0.189 | +7.0% | €2.874 | €2.874 | €2.874 | 0 | |
| €2.685 | -0.204 | -7.1% | €2.685 | €2.685 | €2.685 | 0 | |
| €2.889 | -0.110 | -3.7% | €2.889 | €2.889 | €2.889 | 0 | |
| €2.999 | +0.293 | +10.8% | €2.999 | €2.999 | €2.999 | 0 | |
| €2.706 | +0.110 | +4.2% | €2.706 | €2.706 | €2.706 | 0 |
- Ticker
- Frankfurt:ZVAA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Latest earnings call · May 11, 2026
Cellectis (Euronext:ALCLS) Q1 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Nov 13, 2026
Closed €1.17 (-2.3%) on Nov 13, 2026
Cellectis to Report Third Quarter Financial Results on November 12, 2026
Nov 9, 2026
Closed €0.892 (+4.6%) on Nov 9, 2026
Monthly information on share capital and company voting rights
Nov 4, 2026
Closed €0.928 (+10.1%) on Nov 4, 2026
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with.HEAL-101 at ESGCT 2026
Oct 27, 2026
Closed €0.813 (-2.9%) on Oct 27, 2026
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Sep 14, 2026
Closed €2.60 (-0.6%) on Sep 14, 2026
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
Sep 13, 2026
Closed €2.60 (-0.6%) on Sep 14, 2026
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
Sep 10, 2026
Closed €2.61 (-2.1%) on Sep 11, 2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Sep 2, 2026
Closed €2.82 (+3.9%) on Sep 3, 2026
Cellectis Announces Participation in Upcoming Investor Conferences
Sep 1, 2026
Closed €2.72 (-3.6%) on Sep 2, 2026
Cellectis annonce sa participation à plusieurs conférences investisseurs
Aug 31, 2026
Closed €2.82 (-5.2%) on Sep 1, 2026
Cellectis S.A. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 47 in all · newest Nov 13, 2026 · oldest 2025
- Calls
- 12 calls with a replay · 12 with a transcript · latest May 11, 2026
- Decks
- 35 decks · latest November 2026
Where Cellectis S.A. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ALCLS · Home listing | Euronext | France | EUR |
| NASDAQ:CLLS | NASDAQ | United States | USD |
| gettex:ZVA | gettex | Germany | EUR |
| LS Exchange:A0MKPR | LS Exchange | Germany | EUR |
| LSIN:0WA2 | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A0MKPR | Lang & Schwarz | Germany | EUR |
| Tradegate:ZVA | Tradegate | Germany | EUR |
| BOATS:CLLS | BOATS | United States | USD |
| gettex:ZVAA | gettex | Germany | EUR |
| Lang & Schwarz:A14QZE | Lang & Schwarz | Germany | EUR |
| Munich:ZVA | Munich | Germany | EUR |
| Hamburg:ZVA | Hamburg | Germany | EUR |
| OTC:CMVLF | OTC | United States | USD |
| Tradegate:ZVAA | Tradegate | Germany | EUR |
| Aquis:ALCLSP | Aquis | United Kingdom | EUR |
| Aquis:ALCLSP | Aquis | United Kingdom | EUR |
| Dusseldorf:ZVA | Dusseldorf | Germany | EUR |
| Dusseldorf:ZVAA | Dusseldorf | Germany | EUR |
| Frankfurt:ZVA | Frankfurt | Germany | EUR |
| Frankfurt:ZVAA · This page | Frankfurt | Germany | EUR |
| LS Exchange:A14QZE | LS Exchange | Germany | EUR |
| Stuttgart:ZVA | Stuttgart | Germany | EUR |
| Stuttgart:ZVAA | Stuttgart | Germany | EUR |
| Turquoise:ALCLSP | Turquoise | United Kingdom | EUR |
Valuation
EV/sales −0.2× against a median of 74.5×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −€8.78M EUR
- P/E
- Loss
- EV/sales
- −0.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- 74.7%
- Operating margin
- −107.9%
- Net margin
- −115.4%
- Debt to equity
- 2.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Recce Pharmaceuticals Ltd. · ASX:RCE | US$75.90M | US$81.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Black Diamond Therapeutics, Inc. · NASDAQ:BDTX | US$75.28M | −US$10.71M | n/a | n/a | n/a | 0.8× | n/a | 0.2× | 1.76 |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.93M | US$52.73M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Kanaph Therapeutics Inc. · KRX:0082N0 | US$72.81M | US$39.07M | n/a | 9.3× | n/a | 2.1× | −729.8% | 0.0× | n/a |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.06M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| SynAct Pharma AB · OMXSTO:SYNACT | US$71.20M | US$71.51M | n/a | n/a | n/a | 5.1× | n/a | 0.3× | n/a |
| Bioton S.A. · GPW:BIO | US$70.63M | US$86.88M | n/a | 1.4× | 6.5× | 0.5× | −3.3% | 0.1× | n/a |
| Median of the others | US$73.25M | US$66.45M | 74.5× | 6.5× | 2.4× | −356.9% | 0.1× | 1.16 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.50 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.74 · 1 analyst
- Revenue, year to Dec 2026
- 56.24M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| André Choulika | Chief Executive Officer & Director |
| Patricia Sosa Navarro | Chief of Staff to the CEO |
| Arthur Stril | Chief Financial Officer & Chief Business Officer |
| Marie-Bleuenn Terrier | General Counsel |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director |
| Kyung Nam-Wortman | Executive Vice President, Chief Human Resources Officer |
| Steve Doares | Senior Vice President, US Manufacturing and Site Head |
| Adrian Kilcoyne | Chief Medical Officer |
| Philippe Duchateau | Chief Scientific Officer |
| Stephan Reynier | Chief Regulatory and Pharmaceutical Compliance Officer |
Board
| Director | Role |
|---|---|
| Jean-Pierre Garnier | Chairman of the Board of Directors - Director |
| André Choulika | Chief Executive Officer & Director |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director |
Events
- Next results
- Mar 18, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Cellectis (Euronext:ALCLS) Q1 2026 Earnings Call | Mon, May 11, 2026 | Replay |
| Cellectis (Euronext:ALCLS) Q4 2025 Earnings Call | Fri, Mar 20, 2026 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2024 Earnings Call | Fri, Mar 14, 2025 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q1 2024 Earnings Call | Wed, May 29, 2024 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q2 2023 Earnings Call | Fri, Aug 04, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q1 2023 Earnings Call | Fri, May 05, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2022 Earnings Call | Thu, Mar 09, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q3 2022 Earnings Call | Fri, Nov 04, 2022 · 8:00 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Cellectis (Euronext:ALCLS) Q2 2022 Earnings Call | Fri, Aug 05, 2022 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2021 Earnings Call | Fri, Mar 04, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 · After close | −17.5% |
| Q2 2026 | Aug 6, 2026 · After close | −0.5% |
| Q1 2026 | May 11, 2026 · After close | +1.7% |
| Q4 2025 | Mar 19, 2026 · After close | −1.4% |
| Q3 2025 | Nov 7, 2025 · After close | +12.2% |
| Q2 2025 | Aug 4, 2025 · After close | −15.1% |
| Q1 2025 | May 12, 2025 · After close | −1.3% |
| Q4 2024 | Mar 13, 2025 · After close | −1.9% |
| Q3 2024 | Nov 4, 2024 · After close | −1.5% |
| Q2 2024 | Aug 6, 2024 · After close | +3.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 29, 2024 · After close | −0.6% |
| Q4 2023 | Mar 13, 2024 · After close | −1.2% |
| Q3 2023 | Nov 6, 2023 · After close | −1.8% |
| Q2 2023 | Aug 3, 2023 · After close | −1.6% |
| Q1 2023 | May 4, 2023 · After close | +1.7% |
| Q4 2022 | Mar 8, 2023 · After close | −3.1% |
| Q3 2022 | Nov 3, 2022 · After close | −5.7% |
| Q2 2022 | Aug 4, 2022 · After close | +9.4% |
| Q1 2022 | May 12, 2022 · After close | +1.6% |
| Q4 2021 | Mar 3, 2022 · After close | −3.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 35 slides | November 2026 |
| Corporate Update (September 2026) | Corporate update | 40 slides | Sep 14, 2026 |
| Corporate Update (September 2026) | Corporate update | 40 slides | Sep 14, 2026 |
| Corporate Update (September 2026) | Corporate update | 41 slides | Sep 14, 2026 |
| EHA 2026 | Conference | 23 slides | Jun 15, 2026 |
| Investor Day (June 2026) | Investor day | 65 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 31 slides | May 11, 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 2026 |
| Investor Presentation (November 2025) | Investor deck | 32 slides | November 2025 |
| Investor Day (October 2025) | Investor day | 65 slides | Oct 17, 2025 |
All 35 decks
IPO
Priced at US$41.50 an ADS on Mar 24, 2015.
- Price
- US$41.50 an ADS
- ADSs offered
- 5,500,000 American depositary shares
- Offering size
- US$228.3 million
- Underwriters' option
- Up to 825,000 more ADSs
- Underwriters
- BofA Merrill Lynch, Jefferies, Piper Jaffray, Oppenheimer & Co., Trout Capital · In the order on the cover
- ADSs delivered
- On or about Mar 30, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 19, 2014 |
| Filed publicly | Feb 20, 2015 |
| Amended 4 times | Newest Mar 24, 2015 |
| Shares registered with an exchange | Mar 23, 2015 |
| Declared effective by the SEC | Mar 24, 2015 |
| Final prospectus, with the price | Mar 26, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Mar 26, 2015 |
| EFFECT · Notice that a registration is effective | Mar 24, 2015 |
| F-1MEF · Registration of more shares for the same offering | Mar 24, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Mar 24, 2015 |
| FWP · Free writing prospectus | Mar 24, 2015 |
| F-1/A · Registration statement, amended | Mar 24, 2015 |
| CORRESP · Letter to the SEC | Mar 23, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 23, 2015 |
| F-1/A · Registration statement, amended | Mar 18, 2015 |
| F-1/A · Registration statement, amended | Mar 12, 2015 |
All 19 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Mar 10, 2015 |
| F-1 · Registration statement | Feb 20, 2015 |
| DRS/A · Draft registration statement, amended | Feb 12, 2015 |
| DRSLTR · Letter to the SEC with a draft | Feb 12, 2015 |
| UPLOAD · Letter from the SEC | Feb 9, 2015 |
| DRSLTR · Letter to the SEC with a draft | Jan 27, 2015 |
| DRS/A · Draft registration statement, amended | Jan 27, 2015 |
| UPLOAD · Letter from the SEC | Jan 16, 2015 |
| DRS · Draft registration statement | Dec 19, 2014 |
Open IPO · From the cover of the final prospectus (424B1) filed Mar 26, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.9M | 41.5M | 755.0K | 19.2M | 30.3M | 51.1M | 15.2M | 12.7M | 25.2M | 44.8M |
| Cost of revenue | 0 | 0 | 737.0K | 1.77M | 1.84M | 1.95M | 11.4M | 2.74M | 2.62M | 1.69M |
| Gross profit | 55.0M | 41.5M | 18.0K | 17.4M | 37.7M | 37.7M | 3.80M | 9.99M | 22.6M | 40.9M |
| Research and development | 93.5M | 90.5M | 87.6M | 97.5M | 117.8M | 77.0M | 92.0M | 76.6M | 79.2M | 78.5M |
| Selling, general and administrative | 19.8M | 19.1M | 16.8M | 17.5M | 22.9M | 22.5M | 43.0M | 47.2M | 44.8M | 43.4M |
| Operating income | -33.1M | -59.6M | -97.3M | -89.7M | -103.5M | -42.3M | -123.6M | -105.1M | -92.7M | -67.3M |
| Depreciation and amortization | 20.1M | 19.8M | 18.5M | 18.4M | 14.2M | 7.83M | 6.88M | 2.38M | 3.37M | 2.21M |
| EBITDA | -13.0M | -39.7M | -78.8M | -71.2M | -89.3M | -34.5M | -116.7M | -102.7M | -89.3M | -65.1M |
| Interest expense | 51.1M | 21.6M | 40.6M | 371.0K | 368.0K | 73.0K | 3.00K | 39.0K | 0 | 7.10M |
| Income before tax | -68.0M | -36.8M | -116.5M | -98.6M | -96.7M | -53.6M | -115.2M | -88.3M | -103.7M | -67.3M |
| Income tax | -423.0K | 0 | 371.0K | 87.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -67.6M | -36.8M | -101.1M | -106.1M | -114.2M | -81.1M | -102.1M | -78.7M | -99.4M | -67.3M |
| Earnings per share, basic | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 | -2.41 | -1.93 | -2.78 | -1.91 |
| Earnings per share, diluted | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 | -2.41 | -1.93 | -2.78 | -1.91 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 61.5M | 143.3M | 136.7M | 93.2M | 185.6M | 241.1M | 340.5M | 451.5M | 256.4M | 254.6M |
| Short-term investments | 147.1M | 117.1M | 67.1M | 7.91M | 499.0K | 27.1M | 20.4M | 388.0K | 40.6M | 36.5M |
| Receivables | 14.4M | 6.71M | 569.0K | 772.0K | 20.4M | 5.17M | 2.96M | 2.97M | 2.75M | 3.63M |
| Inventory | 89.7M | 0 | 0 | 1.60M | 2.90M | 275.0K | 250.0K | 118.0K | ||
| Current assets | 236.2M | 287.1M | 233.0M | 122.0M | 225.4M | 315.4M | 391.5M | 487.6M | 323.2M | 312.5M |
| Property, plant and equipment | 38.8M | 45.9M | 54.7M | 63.6M | 78.8M | 71.7M | 23.7M | 8.73M | 7.23M | 16.9M |
| Goodwill | -1.00K | 1.00K | -1.00K | 0 | ||||||
| Total assets | 324.7M | 383.5M | 334.3M | 261.2M | 382.1M | 469.5M | 467.5M | 500.8M | 332.9M | 331.4M |
| Accounts payable | 17.3M | 18.7M | 19.1M | 21.5M | 23.8M | 24.6M | 29.3M | 15.9M | 9.46M | 9.72M |
| Current liabilities | 145.8M | 166.3M | 155.1M | 48.1M | 49.3M | 52.0M | 62.6M | 46.9M | 45.5M | 56.2M |
| Long-term debt | 51.2M | 44.0M | 28.4M | 20.5M | 20.0M | 28.8M | 46.5M | 1.02M | 13.0K | 29.4K |
| Total debt | 90.7M | 91.5M | 85.1M | 82.8M | 102.2M | 111.3M | 47.6M | 1.35M | 34.0K | 1.76M |
| Total liabilities | 248.8M | 252.5M | 249.6M | 135.3M | 145.6M | 160.6M | 112.0M | 50.6M | 47.0M | 56.6M |
| Shareholders' equity | 75.9M | 131.0M | 84.7M | 118.0M | 221.3M | 283.8M | 315.1M | 409.3M | 264.9M | 272.8M |
| Shares outstanding | 100.3M | 100.1M | 71.8M | 45.7M | 45.5M | 42.8M | 42.5M | 42.4M | 36.0M | 35.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39.4M | 23.0M | -24.7M | -87.4M | -104.6M | -80.3M | -69.1M | -68.1M | -52.3M | -32.7M |
| Capital spending | -2.36M | -2.58M | -1.07M | -2.43M | -18.5M | -44.1M | -12.9M | -4.71M | -2.38M | -13.7M |
| Free cash flow | -41.8M | 20.4M | -25.8M | -89.9M | -123.1M | -124.3M | -82.1M | -72.9M | -54.7M | -46.4M |
| Cash from investing | -29.5M | -102.8M | -15.5M | -2.76M | 7.28M | -54.3M | -35.9M | 35.6M | 1.78M | -53.1M |
| Cash from financing | -16.8M | 89.1M | 82.9M | 1.15M | 47.5M | 27.3M | -3.86M | 236.5M | 41.3M | 485.0K |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Share buybacks | 44.0K | 82.8M | 67.9M | -569.0K | 15.5M | 9.55M | -469.0K | 186.7M | 3.05M | -137.0K |
| Change in cash | -85.6M | 9.29M | 42.6M | -89.1M | -49.8M | -107.3M | -108.9M | 204.0M | -9.28M | -85.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update | Nov 13, 2026 | Results | Euronext |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| Cellectis to Report Third Quarter Financial Results on November 12, 2026 | Nov 9, 2026 | Results | Euronext |
| Monthly information on share capital and company voting rights | Nov 4, 2026 | Other filings | Euronext |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 | Oct 27, 2026 | Other filings | Euronext |
| 6-K · Report of a foreign issuer | Sep 14, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 547 filings. Open Filings
Cap table
Built by 6ix from Cellectis S.A.’s releases
- Common shares
- 72,732,781
- Fully diluted
- 72,732,781
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 72,732,781 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 72,732,781 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adrian Kilcoyne | Chief Medical Officer · Since at least May 12, 2026 |
| André Choulika | Chief Executive Officer & Director · Since at least Sep 14, 2026 |
| Arthur Stril | Chief Financial Officer & Chief Business Officer · Since at least Oct 27, 2026 |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director · Since at least May 29, 2026 |
| Jean-Pierre Garnier | Chairman of the Board of Directors - Director · Since at least May 29, 2026 |
| Kyung Nam-Wortman | Executive Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Marie-Bleuenn Terrier | General Counsel · Since at least Nov 5, 2026 |
| Patricia Sosa Navarro | Chief of Staff to the CEO · Since at least Oct 27, 2026 |
| Philippe Duchateau | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Stephan Reynier | Chief Regulatory and Pharmaceutical Compliance Officer · Since at least Nov 5, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Steve Doares | Senior Vice President, US Manufacturing and Site Head · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Cellectis S.A.